202 related articles for article (PubMed ID: 35460475)
1. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
[TBL] [Abstract][Full Text] [Related]
2. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Ikeda T; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Target Oncol; 2023 Mar; 18(2):209-220. PubMed ID: 36941516
[TBL] [Abstract][Full Text] [Related]
5. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
7. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
[TBL] [Abstract][Full Text] [Related]
9. Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.
Dong H; Cao Y; Jian Y; Lei J; Zhou W; Yu X; Zhang X; Peng Z; Sun Z
BMC Cancer; 2023 Oct; 23(1):943. PubMed ID: 37803307
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
Ishihara H; Fukuda H; Takagi T; Kondo T; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Int J Urol; 2021 Jan; 28(1):99-106. PubMed ID: 33159426
[TBL] [Abstract][Full Text] [Related]
11. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
Tzeng A; Tzeng TH; Ornstein MC
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599022
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
[TBL] [Abstract][Full Text] [Related]
13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
15. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma.
Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Hashimoto Y; Kondo T; Takagi T
Jpn J Clin Oncol; 2023 Oct; 53(10):977-983. PubMed ID: 37519060
[TBL] [Abstract][Full Text] [Related]
19. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
